Selected article for: "cytokine release and immune response"
Author: Buonaguro, Franco Maria; Puzanov, Igor; Ascierto, Paolo Antonio
Title: Anti-IL6R role in treatment of COVID-19-related ARDS
  • Document date: 2020_4_14
    • ID: 0pigqtzt_10
    Snippet: The clinical presentation of patients with severe forms of COVID-19 resembles cytokine release syndrome (CRS) observed in some oncology patients treated with CAR-T cell therapies. There, IL-6R inhibition with tocilizumab (anti-IL-6R antibody) proved effective and was FDA approved in 2017. IL-6 and its receptor signaling were shown to play a role in immune response to H1N1 influenza and prevention of lung damage [3] [4] [5] . However, administrati.....
    Document: The clinical presentation of patients with severe forms of COVID-19 resembles cytokine release syndrome (CRS) observed in some oncology patients treated with CAR-T cell therapies. There, IL-6R inhibition with tocilizumab (anti-IL-6R antibody) proved effective and was FDA approved in 2017. IL-6 and its receptor signaling were shown to play a role in immune response to H1N1 influenza and prevention of lung damage [3] [4] [5] . However, administration of tocilizumab has not prevented influenza vaccination immune response in patients with rheumatoid arthritis [6] . its role in patients infected with SARS-CoV-2 has not yet been fully studied and is awaiting completion of clinical trials under way.

    Search related documents:
    Co phrase search for related documents
    • anti tocilizumab antibody and clinical trial: 1, 2, 3
    • anti tocilizumab antibody and CRS cytokine release syndrome: 1
    • anti tocilizumab antibody and cytokine release: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • anti tocilizumab antibody and cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • anti tocilizumab antibody and H1N1 influenza: 1
    • anti tocilizumab antibody and immune response: 1, 2, 3
    • anti tocilizumab antibody and immune response role: 1
    • anti tocilizumab antibody and lung damage: 1, 2
    • cell therapy and clinical presentation: 1, 2, 3, 4, 5, 6
    • cell therapy and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell therapy and CRS cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell therapy and cytokine release: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell therapy and cytokine release syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell therapy and H1N1 influenza: 1
    • cell therapy and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell therapy and immune response role: 1, 2
    • cell therapy and influenza vaccination: 1, 2
    • clinical presentation and CRS cytokine release syndrome: 1, 2
    • clinical presentation and cytokine release: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15